Peptide that contains modified sequence of the gp 100 epitope gp(209-217), in which a methionine replaced the natural threonine at position 2. This peptide also binds to the HLA-A2 molecule with greater affinity than the unmodified peptide and has exhibited a good ability to stimulate melonomareactive cytotoxic T lymphocytes (CTLs) in vitro when used for sensitization of peripheral blood mononuclear cells. This synthetic peptide holds promise for the development of novel cancer immunotherapies. MW: 920.2 Da. Purity >98 % purified